Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation
NCCN Guidelines for Cervical Cancer now include Puma's neratinib monotherapy for 2nd line or later use in patients with ...